GlassScriptPhysician profile
Rozy D Dunham
NPI 1164576872
$2,785.00
in general payments reported to CMS, 2019-2025
24 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $103 · 2021: $303 · 2022: $377 · 2023: $433 · 2024: $170 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $461.89 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $350.09 | 2019-2025 | |
| Boston Scientific Corporation | $349.64 | 2021-2024 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.86 | 2019-2025 | Jardiance |
| Abiomed | $254.84 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $239.45 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $191.77 | 2019-2023 | Camzyos |
| Atricure, INC. | $146.54 | 2023 | |
| American Regent | $99.10 | 2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $51.26 | 2019-2023 | Farxiga |
| Pfizer INC. | $47.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $44.12 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $38.96 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $27.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.61 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $23.30 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2025 | |
| Irhythm Technologies, INC. | $17.54 | 2022 | |
| Cvrx, INC. | $17.18 | 2024 | Barostim Neo System |
| Teleflex LLC | $15.14 | 2020 | |
| Abbott Laboratories | $14.89 | 2019 | |
| Astellas Pharma US INC | $13.91 | 2019 | |
| Kestra Medical Technology Services, INC. | $13.10 | 2023 | Assure Wcd |
| W. L. Gore & Associates, INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rozy Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.